Page last updated: 2024-10-16

carbamates and Cancer of Rectum

carbamates has been researched along with Cancer of Rectum in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer."1.72Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases. ( Alfallouji, Y; Borysiewicz, C; Bunker, CB; Calonje, E; Hodgkinson, T; Perrett, CM; Sidwell, RU; Spencer, A; Wasan, H; Watchorn, R, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Alfallouji, Y1
Spencer, A1
Calonje, E1
Perrett, CM1
Watchorn, R1
Borysiewicz, C1
Hodgkinson, T1
Wasan, H1
Bunker, CB1
Sidwell, RU1
Ajani, JA1
Hortobagyi, GN1
Frye, D1
Levin, B1
Boman, BM1
Faintuch, JS1

Trials

1 trial available for carbamates and Cancer of Rectum

ArticleYear
A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma.
    American journal of clinical oncology, 1987, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Carbamates; Carcinoma; Clinical Trials as Topic; Colonic Neoplasms; Humans; P

1987

Other Studies

1 other study available for carbamates and Cancer of Rectum

ArticleYear
Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Exanthema; Humans; Mu

2022